Comparison of Efficacy and Safety of Atorvastatin Versus Combination of Atorvastatin - Ezetimibe in Newly Diagnosed Dyslipedemic Patients
Journal of Pharmaceutical Research International,
Hypercholesterolemia is a major risk factor for cardiovascular disease. Low-density lipoprotein cholesterol is an established risk factor for atherosclerotic disease, particularly coronary artery disease (CAD); therefore, management of high serum LDL-C levels is the most important goal in the treatment of dyslipidemia. Since therapy with statins alone fails to achieve the targeted LDL-C values with lesser side effects it is better to try a combination therapy having high efficacy and safety profile. This study compared the efficacy and safety of the combination of Atorvastatin 10 mg +Ezetimibe 10 mg versus Atorvastatin 10 mg alone in lowering LDL-C in newly diagnosed dyslipidemic patients. Besides, it compared the efficacy of the two drugs in lowering the TC, TG, and TC/HDL-C and LDL/HDL-C ratio. We also compared the increase in HDL-C in the two groups at the end of 12 weeks. This study was conducted on 60 hypercholesterolemic patients in SreeBalaji Medical College Hospital. The patients were randomly divided into two groups of 30each. Group 1 was given Atorvastatin 10 mg +Ezetimibe 10 mg while Group 2 was given Atorvastatin 10 mg. The Lipid Profile, biochemical and hematological tests, clinical examination were done on Day 0, 6th week, and 12th week and these results were compared the group and between groups from 0 to 6th week and 6th week to 12th week and 0 to 12th week. The results from our study indicated that Combination therapy with Atorvastatin 10 mg + Ezetimibe 10 mg is superior to Atorvastatin 10 mg alone in reducing LDL-C, TC, TC/HDL-C ratio and raising the HDL-C levels at the end of 12 weeks. Thus the study implies that combination therapy is superior to monotherapy in the high-risk group of dyslipidemia patients.
How to Cite
Therapeutic Lipidology Edited by Michael H. Davidson, md, facc, facp, Peter P. Toth, md, phd, faap, fica, faha, fccp, facc, Kevin C. Maki, phd.
Treatment of dyslipidemia in patients with type 2 diabetes Krishnaswami Vijayaraghavan.Vijayaraghavan Lipids in Health and Disease. 2010;9:144.
Current lipid management and low cholesterol goal attainment in common daily practice in Spain. The Reality Study. Pharmacoeconomics. 2004;22(Suppl3):1-12.
Hermans MP1, Castro Cabezas M, Strandberg T, Ferrières J, Feely J, Elisaf M, Michel G, Sansoy V. Centralized pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): Overall findings from eight countries. Curr Med Res Opin. 2010;26(2):445-54.
Dean G, Karalis, Brett Victor, Lilian Ahedor, Longjian Liu. Use of lipid-lowering medications and the likelihood of achieving optimal LDL-cholesterol goals in coronary artery disease patients. Cholesterol. 2012;Article ID 861924:7.
Nutescu EA1, Shapiro NL. Ezetimibe: A selective cholesterol absorption inhibitor. Pharmacotherapy. 2003No;23(11):1463-74.
BaysH1. Ezetimibe. Expert opininvestig drugs. 2002;11(11):1587-604.
Amir Kashani, MS MDa, Tamer Sallam MDa, Swarna Bheemreddy MDa, b, Douglas L. Mann, MDe, Yun Wang, d, JoAnne M. Foody MDf. Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials; 2008.
Graf K, Dietrich T, Tachezy M, et al. Monitoring therapeutical intervention with ezetimibe using targeted near-infrared fluorescence imaging in experimental atherosclerosis. Mol Imaging. 2008;7(2):68–76.
Christopher J O'Donnella, Roberto Elosuab. Cardiovascular Risk factors. insights from framingham heart study. Rev Esp Cardiol. 2008;61(03): 299-310.
Jeremiah Stamler, Deborah Wentworth, James D. Neaton. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded?Findings in 356 222 Primary Screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256(20):2823-2828.
Lipid research clinics (LRC) coronary primary prevention trial. The lipid research clinics coronary primary prevention trial program. I. Reduction in incidence of coronary heart disease. 1984;jama.251:351-364.
Christie M Ballantyne, John Houri, Alberto Notarbartolo, Lorenzo Melani, Leslie J Lipka, Ramachandran Suresh, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia a prospective, randomized, double-blind trial. for the Ezetimibe Study Group; 2003.
Wolffenbuttel BH1, Mahla G, Muller D, Pentrup A, Black DM. Efficacy and safety of a new cholesterol synthesis inhibitor, atorvastatin, in comparison with simvastatin and pravastatin, in subjects with hypercholesterolemia; 1998.
Stephen P Adams1, Michael Tsang2, James MWright1. Lipid-lowering efficacy of atorvastatin; 2015.
Thomas Sudhop, Dieter Lütjohann, Annette Kodal MS, Michael Igel, Diane L Tribble, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans; 2002.
Claude Gagné, Harold E Bays, Stuart R Weiss, Pedro Mata, Katherine Quinto BSN, Michael Melino RN, Meehyung Cho, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia; 2002.
Frederick F Samaha, James McKenney, LeAnne T Bloedon, William J Sasiela, Daniel J Rader. Inhibition of microsomal triglyceride transfer protein alone or with Ezetimibe in patients with moderate hypercholesterolemia; 2008.
Knopp RH1, GitterH, Truitt T, Bays H, Manion CV, Lipka LJ, LeBeaut AP, Suresh R, Yang B, Veltri EP. Eezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hyperchole sterolemia. Ezetimibe Study Group; 2003.
Abstract View: 0 times
PDF Download: 0 times